GI-5005
Identification
- Generic Name
- GI-5005
- DrugBank Accession Number
- DB05942
- Background
GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Recombinant - Synonyms
- Not Available
- External IDs
- GI 5005
- GI-5005
Pharmacology
- Indication
Investigated for use/treatment in hepatitis (viral, C).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
The mechanism of action for GI-5005 (i.e. immune elimination of infected hepatic cells) may work synergistically in combination with the current or emerging standard of care, which directly inhibits viral replication, to more effectively eradicate hepatitis C virus from the liver. Additionally, this mechanism of action may offer an option for interferon-intolerant or interferon-contraindicated patients as a long term monotherapy.
GI-5005 is designed to elicit a cellular immune response against cells infected with the HCV virus. The yeast vector is designed not only to stimulate an innate immune response mediated by Toll-like receptors (TLRs), but also to deliver target protein directly to antigen presenting cells, eliciting an antigen-specific helper T cell (CD4) and killer T cells (CD8) cellular immune response to eliminate diseased cells.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of GI-5005 can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of GI-5005 can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of GI-5005 can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 1001913-27-4
References
- General References
- Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC: Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007 Feb 9;25(8):1452-63. Epub 2006 Nov 10. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Chronic Hepatitis C Genotype 1 1 1 Completed Treatment Hepatitis C Virus (HCV) Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at November 18, 2007 18:28 / Updated at June 12, 2020 16:52